Skip to main content

Co-Diagnostics, Inc.

corporate_fare Company Profile

Co-Diagnostics, Inc.

CODX·NASDAQ·Industrial Applications And Services·CIK 0001692415

Co-Diagnostics, Inc. develops, manufactures, and sells reagents for diagnostic tests that detect and analyze nucleic acid molecules (DNA or RNA), including molecular tools for infectious diseases. The company's diagnostic systems aim to provide dependable, low-cost molecular testing by simplifying complex procedures in test development and administration. Co-Diagnostics' technology uses a proprietary approach to polymerase chain reaction (PCR) test design, called Co-Primers®, which reduces primer-dimer amplification (false positives) that can interfere with identifying target DNA/RNA. Using this system and reagents, the company has designed and obtained regulatory approval to sell PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the Zika virus. These initial diagnostic tests are cleared for use only in clinical labs. Co-Diagnostics has also developed a portable diagnostic device and test system for point-of-care and at-home use, referred to as the "Co-Dx™ PCR platform." This system includes the Co-Dx™ PCR Pro® instrument, a patent-pending diagnostic test cup system, and a mobile application. The Co-Dx PCR platform is designed to offer affordable, reliable PCR testing in point-of-care and at-home settings. This platform is currently subject to U.S. Food and Drug Administration (FDA) review and is not available for sale at the time of this filing. In June 2024, the company completed its first FDA 510(k) clearance application for the Co-Dx PCR Pro instrument, the Co-Dx PCR COVID-19 Test, and the Co-Dx PCR mobile app for over-the-counter (OTC) use.

Co-Diagnostics, Inc. (NASDAQ:CODX) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 36 items for CODX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Resale Registration Filed for 4.9M Shares from Deeply Discounted Private Placement
  • Co-Diagnostics Advances Ebola Assay Development with CoSara Amid Global Health Emergency
  • Co-Diagnostics Secures $3.0M Private Placement at Deep Discount Amid Going Concern
  • $3M Private Placement with Warrants Announced by Co-Diagnostics
  • Co-Diagnostics Reports Widening Loss, Critical Cash Burn, and Expired ATM Program Amid Going Concern Warning

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$622.49K
Net Income
-$46.9M
Diluted EPS
-$35.25
Op. Cash Flow
-$29.14M
Free Cash Flow
-$29.84M
Gross Profit
$400.11K
Operating Income
-$50.17M
Cash & Equivalents
$11.88M
Debt / Equity
0.00×
Net Margin
-75.34×
Shares Outstanding
2.1M sh
Source: 10-K · filed 2026-03-31 · accession 0001493152-26-014158
$0.1332 +2.86% today
52-week range · as of 2026-11-20 $0.1276 – $13.54
Market cap
$1.69M
Volume
1.1M (0.3× avg)
3-mo avg 4M
Live data · 2026-11-22 12:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CODX - Filings & News (Page 2)

CODX
May 28, 2026, 4:30 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $10.80
Real-time Price: $0.1332 info
Change: Reverse Stock Split info
Market Cap: $1.689M info
CODX
May 26, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $6.97
Real-time Price: $0.1332 info
Change: Reverse Stock Split info
Market Cap: $1.689M info
CODX
May 21, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.83
Real-time Price: $0.1332 info
Change: Reverse Stock Split info
Market Cap: $1.689M info
CODX
May 19, 2026, 10:54 PM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $2.18
Real-time Price: $0.1332 info
Change: Reverse Stock Split info
Market Cap: $1.689M info
CODX
May 14, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.59
Real-time Price: $0.1332 info
Change: Reverse Stock Split info
Market Cap: $1.689M info
CODX
May 14, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1.63
Real-time Price: $0.1332 info
Change: Reverse Stock Split info
Market Cap: $1.689M info
CODX
May 12, 2026, 4:39 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $1.71
Real-time Price: $0.1332 info
Change: Reverse Stock Split info
Market Cap: $1.689M info
CODX
May 12, 2026, 4:30 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $1.73
Real-time Price: $0.1332 info
Change: Reverse Stock Split info
Market Cap: $1.689M info
CODX
May 08, 2026, 9:03 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.21
Real-time Price: $0.1332 info
Change: Reverse Stock Split info
Market Cap: $1.689M info
CODX
Apr 02, 2026, 9:42 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.57
Real-time Price: $0.1332 info
Change: Reverse Stock Split info
Market Cap: $1.689M info
CODX
Mar 31, 2026, 4:10 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.77
Real-time Price: $0.1332 info
Change: Reverse Stock Split info
Market Cap: $1.689M info
CODX
Mar 31, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
10
Price at Filing: $1.86
Real-time Price: $0.1332 info
Change: Reverse Stock Split info
Market Cap: $1.689M info
CODX
Mar 27, 2026, 4:23 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $1.75
Real-time Price: $0.1332 info
Change: Reverse Stock Split info
Market Cap: $1.689M info
CODX
Mar 20, 2026, 1:37 PM EDT
Source: FinanceWire
Importance Score:
8
Price at Filing: $2.59
Real-time Price: $0.1332 info
Change: Reverse Stock Split info
Market Cap: $1.689M info
CODX
Mar 10, 2026, 9:25 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.18
Real-time Price: $0.1332 info
Change: Reverse Stock Split info
Market Cap: $1.689M info
CODX
Jan 13, 2026, 12:23 PM EST
Filing Type: 8-K
Importance Score:
10
Price at Filing: $2.40
Real-time Price: $0.1332 info
Change: Reverse Stock Split info
Market Cap: $1.689M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets